Nutraceutical Expansion Ceapro's flagship oat-derived ingredients, including oat beta glucan and avenanthramides, are being expanded for nutraceutical applications, signaling cross-selling opportunities to nutraceutical brands and functional foods looking for evidence-based heart health and anti-inflammatory benefits.

Cosmetic and Personal Care Alignment The company already supplies ingredients to major cosmetic brands and utilizes proprietary oat extraction processes, presenting a clear route to partnerships with skincare and topical product developers seeking natural antioxidants, anti-inflammatory actives, and collagen-supporting ingredients.

Bioactive Platform Ceapro’s PGX technology and biopolymer processing capabilities enable high-value nano-sized polymer structures and bio-nanocomposites, offering partnerships with pharma, biotech, and advanced materials clients pursuing novel delivery systems or regenerative therapies.

Strategic Growth via Merger Recent merger activity with Aeterna Zentaris and ongoing clinical development of avenanthramide formulations indicate potential for co-development opportunities, licensing, and collaborative trials with healthcare and life sciences partners.

R&D to Pilot Commercialization Investment in pilot-scale units for PGX processing and ongoing Q1 2024 advancements in avenanthramide clinical programs suggest readiness to pilot and scale supply agreements with manufacturers needing scalable, compliant production of plant-based actives.